人 NK 细胞来源纳米魔弹针对急性髓系白血病（AML）的抗白血病活性

Background: Cancer is among the serious health problems of the medical world, for treatment of which severe treatments are used.

However, the prognosis of cancer patients is still poor. The application of NK cell-derived exosomes (NK-Exo) is a new method for cancer immunotherapy. These nanoparticles with a size range of 30-120 nm are a small model of mother cells. In this study, the anti-tumor activity of NK-Exo and LAK-Exo (activated NK cell-derived exosome) against acute myeloid leukemia (AML) is investigated in vitro. Materials and Methods: The MACS method was performed for the separation of NK cells from the buffy coats of healthy donors, and an EXOCIBE kit was used for the isolation of NK-Exo.

After treating the KG-1 cell line with different doses of NK-Exo, MTT assay, and annexin V-PE were done to evaluate cell proliferation and apoptosis, respectively, and for confirmation of involved proteins, Real-Time PCR and western blotting were performed. Results: Anti-tumor activity of NK-Exo and LAK-Exo was dose- and time-dependent. Their highest activities were observed following 48 hours of incubation with 50 g/ml exosome (p<0. 0001).

However, this cytotoxic activity was also seen over a short period of time with low concentrations of NK-Exo (p<0. 05) and LAK-Exo (p<0. 001). The cytotoxic effect of LAK-Exo on target cells was significantly higher than NK-EXO. The induction of apoptosis by different pathways was time-point dependent. Total apoptosis was 34.

56% and 51. 6% after 48 hours of tumor cell coculture with 50 g/ml NK-Exo and LAK-Exo, respectively. Significant expression of CASPASE3 , P38, and CYTOCHROME C genes was observed in the cells treated with 50 g/ml NK-Exo and LAK-Exo. Conclusion : Our study confirmed the antileukemia activity of NK-Exo against AML tumor cells in vitro.

Therefore, NK-Exo can be considered as a promising and effective treatment for leukemia therapy.